Patent landscape of small molecule inhibitors of METTL3 (2020-present) DOI
Zhixing Wu, Alexis R. Smith, Zhijian Qian

et al.

Expert Opinion on Therapeutic Patents, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 16

Published: Dec. 25, 2024

Introduction Methyltransferase-like protein 3 (METTL3), in complex with METTL14, is the key 'writer' for RNA m6A methylation, accounting almost all mRNA modifications. Recent studies reveal that METTL3 implicated development and progression of various types cancers. Targeting small molecule inhibitors represents a promising therapeutic strategy cancer.

Language: Английский

Patent landscape of small molecule inhibitors of METTL3 (2020-present) DOI
Zhixing Wu, Alexis R. Smith, Zhijian Qian

et al.

Expert Opinion on Therapeutic Patents, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 16

Published: Dec. 25, 2024

Introduction Methyltransferase-like protein 3 (METTL3), in complex with METTL14, is the key 'writer' for RNA m6A methylation, accounting almost all mRNA modifications. Recent studies reveal that METTL3 implicated development and progression of various types cancers. Targeting small molecule inhibitors represents a promising therapeutic strategy cancer.

Language: Английский

Citations

4